The acquisition of TrialNetworks will enable DrugDev to leverage collaborative trial management software and help its users optimize clinical trial processes.
On 5 May 2014, DrugDev, which provides a service and platforms to create more efficient clinical trials, announced that it has acquired TrialNetworks, a collaborative trial management software vendor. Terms of the deal were not disclosed.
This acquisition will enable DrugDev to extend site services and tools for optimizing clinical trial design to the industry. DrugDev is now in a position to create a unique software and services offering that streamlines optimization of clinical trials across a large global clinical trial investigator network. This will assist pharmaceutical company sponsors and contract research organizations (CROs) with finding and engaging clinical investigators for study design and startup. The offering includes feasibility studies, investigator communities, enrollment challenges, patient retention support, training and activation. Eventually, TrialNetworks' users will be able to use the DrugDev toolset and network to improve connections between the CRO, investigators and sponsors, and gain access to wider regional coverage within more countries.
Even as this acquisition positions DrugDev to be one of the leaders in this new space, it will also spur innovation and competitiveness from other vendors on the periphery to develop technologies and services to better bridge CROs, sponsors and investigators and drive industry efficiency.
DrugDev already offered a platform for connecting sponsors with investigators and CROs, and its purchase of CFS Clinical added clinical trial financial management capabilities for investigator payments and clinical trial site activation. But DrugDev lacked the tools required to optimize clinical trial processes at a site and sponsor level. TrialNetworks technology will give DrugDev this capability through a cluster of apps on a unified cloud-based platform. The TrialNetworks technology spans three key process areas for clinical development:
Workflow and process optimization: Enables study teams and sites to share two-way information and track tasks such as site activation and data management for study closeout.
Engagement and communication: Uses study updates, video interviews, site profiles, recognition badges and leaderboards to build a sense of community, inspire friendly competition and communicate about the sponsor’s trial at global sites.
Training and education: Provides a learning management system with personalized user curriculum, multimedia training modules, interactive assessments and completion certificate tracking.
TrialNetworks has already gained some credibility among major pharmaceutical companies for site engagement, global patient enrollment, and site feasibility surveys. DrugDev will continue to leverage this technology and its CFS Clinical capabilities to expand further into the pharmaceutical sector.
DrugDev sponsor and CRO customers: If you focus on clinical development, investigator relationships and site engagement:
Consider leveraging the expanded TrialNetworks capabilities for clinical trial optimization.
Evaluate whether the TrialNetworks suite of apps and cloud-based architecture can reduce IT complexity and infrastructure costs.
TrialNetworks sponsor and CRO customers:
Reaffirm terms and conditions of license and software agreements.
Consider the broader end-to-end capabilities of DrugDev for driving and modeling site engagement.
Keep touch with TrialNetworks points of contact to ensure a smooth transition.